Allopurinol for the treatment of aggressive behaviour in patients with dementia

被引:37
作者
Lara, DR
Cruz, MRS
Xavier, F
Souza, DO
Moriguchi, EH
机构
[1] Pontificia Univ Catolica Rio Grande do Sul, Fac Biociencias, Dept Ciencias Fisiol, BR-90619900 Porto Alegre, RS, Brazil
[2] Pontificia Univ Catolica Rio Grande do Sul, Inst Geriatr & Gerontol, BR-90619900 Porto Alegre, RS, Brazil
[3] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Dept Bioquim, Porto Alegre, RS, Brazil
关键词
allopurinol; aggression; dementia; Alzheimer; adenosine; free radical;
D O I
10.1097/00004850-200301000-00009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aggressive behaviour is commonly observed in patients with dementia, and current pharmacological treatments are still deficient in terms of efficacy and tolerability. Allopurinol is an inhibitor of the enzyme xanthine oxidase, with previously suggested anti-aggressive effects. After successful treatment of aggression in two patients, we performed a case-series study with allopurinol 300 mg a day orally for 6 weeks (increasing 300 mg every 2 weeks if the response was less than 50%) in six patients with dementia associated with prominent aggressive behaviour who failed to respond to two previous treatment strategies. Five patients were considerably responsive to allopurinol (four with 300 mg within 2 weeks and one with 600 mg), apparently without side-effects, which is in accordance with its well-established safety and tolerability profile. The observed therapeutic effect of allopurinol might be due to the inhibition of the enzyme xanthine oxidase, possibly decreasing production of oxigen-free radicals or promoting the accumulation of purines. Controlled studies are warranted to confirm these preliminary observations. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:53 / 55
页数:3
相关论文
共 26 条
  • [1] Brundege J M, 1997, Adv Pharmacol, V39, P353, DOI 10.1016/S1054-3589(08)60076-9
  • [2] The glutamate synapse in neuropsychiatric disorders - Focus on schizophrenia and Alzheimer's disease
    Farber, NB
    Newcomer, JW
    Olney, JW
    [J]. GLUTAMATE SYNAPSE AS A THERAPEUTICAL TARGET: MOLECULAR ORGANIZATION AND PATHOLOGY OF THE GLUTAMATE SYNAPSE, 1998, 116 : 421 - 437
  • [3] Activation of glutamate uptake by guanosine in primary astrocyte cultures
    Frizzo, MES
    Lara, DR
    Dahm, KCS
    Prokopiuk, AS
    Swanson, RA
    Souza, DO
    [J]. NEUROREPORT, 2001, 12 (04) : 879 - 881
  • [4] Recommendations for the management of behavioral and psychological symptoms of dementia
    Herrmann, N
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2001, 28 : S96 - S107
  • [5] Evaluation of memantine for neuroprotection in dementia
    Jain, KK
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (06) : 1397 - 1406
  • [6] KATSURAGI T, 1984, PHARMACOL BIOCHEM BE, V20, P943
  • [7] Keene J, 1999, INT J GERIATR PSYCH, V14, P541, DOI 10.1002/(SICI)1099-1166(199907)14:7<541::AID-GPS961>3.0.CO
  • [8] 2-P
  • [9] KNOEDLER DW, 1989, AM J PSYCHIAT, V146, P1081
  • [10] Allopurinol augmentation for poorly responsive schizophrenia
    Lara, DR
    Brunstein, MG
    Ghisolfi, ES
    Lobato, MI
    Belmonte-de-Abreu, P
    Souza, DO
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (04) : 235 - 237